Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy

Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or... Adv Ther (2017) 34:1936–1952 DOI 10.1007/s12325-017-0578-8 ORIGINAL RESEARCH Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy . . . . Wenhui Wei Keith Knapp Li Wang Chieh-I Chen . . Gary L. Craig Karen Ferguson Sergio Schwartzman Received: April 26, 2017 / Published online: July 3, 2017 The Author(s) 2017. This article is an open access publication cycled to a TNFi or switched to a new MOA ABSTRACT therapy by March 2015. Cox proportional haz- ards models were used for time to non-persis- Introduction: To examine treatment persis- tence (switching or discontinuing). An ordinary tence and clinical outcomes associated with least squares regression model compared 1-year switching from a tumor necrosis factor inhibitor reduction from baseline for the Clinical Disease (TNFi) to a medication with a new mechanism Activity Index (CDAI). of action (MOA) (abatacept, anakinra, ritux- Results: There were 332 (54.2%) TNFi cyclers imab, tocilizumab, or tofacitinib) versus cycling and 281 (45.8%) new MOA switchers. During a to another TNFi (adalimumab, certolizumab median follow-up of 29.9 months, treatment http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy

Loading next page...
 
/lp/springer_journal/treatment-persistence-and-clinical-outcomes-of-tumor-necrosis-factor-MG3Ad9lu09
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0578-8
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2017) 34:1936–1952 DOI 10.1007/s12325-017-0578-8 ORIGINAL RESEARCH Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy . . . . Wenhui Wei Keith Knapp Li Wang Chieh-I Chen . . Gary L. Craig Karen Ferguson Sergio Schwartzman Received: April 26, 2017 / Published online: July 3, 2017 The Author(s) 2017. This article is an open access publication cycled to a TNFi or switched to a new MOA ABSTRACT therapy by March 2015. Cox proportional haz- ards models were used for time to non-persis- Introduction: To examine treatment persis- tence (switching or discontinuing). An ordinary tence and clinical outcomes associated with least squares regression model compared 1-year switching from a tumor necrosis factor inhibitor reduction from baseline for the Clinical Disease (TNFi) to a medication with a new mechanism Activity Index (CDAI). of action (MOA) (abatacept, anakinra, ritux- Results: There were 332 (54.2%) TNFi cyclers imab, tocilizumab, or tofacitinib) versus cycling and 281 (45.8%) new MOA switchers. During a to another TNFi (adalimumab, certolizumab median follow-up of 29.9 months, treatment

Journal

Advances in TherapySpringer Journals

Published: Jul 3, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off